Prime Medicine Stock

primemedicine.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $315.76MM

Prime Medicine is a gene editing biotechnology company.

Register To Buy and Sell Private Company Shares

For more details on financing and valuation of private companies similar to Prime Medicine before its IPO, register or login today.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Prime Medicine Stock Price

Forge Price 1
Price not available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Prime Medicine Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
07/13/2021 Series B $200MM $xx.xx $1.23B Arch Venture Partners, Casdin Capital, Cormorant Asset Management, F-Prime Capital, Gv, Moore Strategic Ventures, Newpath Partners, Public Sector Pension Investment Board, Redmile Group, Samsara Biocapital, T. Rowe Price
Price per Share
$xx.xx
Shares Outstanding
45,658,957
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Arch Venture Partners, Casdin Capital, Cormorant Asset Management, F-Prime Capital, Gv, Moore Strategic Ventures, Newpath Partners, Public Sector Pension Investment Board, Redmile Group, Samsara Biocapital, T. Rowe Price
10/15/2020 Series A $115.76MM $xx.xx $231.52MM Arch Venture Partners, F-Prime Capital, Gv, Newpath Partners
Price per Share
$xx.xx
Shares Outstanding
115,761,842
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Cumulative
Participating
Participating
Participation Cap
1000
Key Investors
Arch Venture Partners, F-Prime Capital, Gv, Newpath Partners

Prime Medicine Investors Also Invested in These Private Companies

Prime Medicine stock FAQs

plusminus

Can you buy Prime Medicine stock?

You can no longer buy Prime Medicine stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

How to buy Prime Medicine stock?

You can no longer buy Prime Medicine stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.
plusminus

Can you sell Prime Medicine stock?

You can no longer sell stock of Prime Medicine on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

How to sell Prime Medicine stock?

You can no longer sell stock of Prime Medicine on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.
plusminus

Is Prime Medicine a public company?

Prime Medicine is now a public company traded on NASDAQ with ticker PRME.
plusminus

What is Prime Medicine’s stock price?

The stock price of Prime Medicine is $6.39 as of 1/18/24.
plusminus

What is Prime Medicine’s stock ticker symbol?

The ticker symbol of Prime Medicine is PRME.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Prime Medicine News and Media Highlights

Prime Medicine (PRME) Gains 16.4% in 3 Months: Buy Now or Wait?

Prime Medicine, Inc.’s PRME shares have risen 16.4% in the past three months compared with the industry’s growth of 10.9%. The stock has also outperformed the sector and the S&P 500. The encouraging pipeline progress of this biotechnology company, focused on developing the next generation of gene editing therapies, is a positive. Innovation is imperative in the dynamic biotech sector and companies with a differentiated pipeline catch the eye of investors.

Prime Medicine prices IPO for CRISPR 3.0

Prime Medicine, a Cambridge, Mass.-based gene editing company founded by Harvard biochemist David Liu, has raised $175 million in its IPO and will begin trading Thursday on the Nasdaq. The biotech world views this as CRISPR 3.0, from the same man who invented CRISPR 2.0. It's also one of the most successful U.S. IPOs in recent memory, as Prime sold 1.4 million shares more than expected while hitting the middle of its $17-$19 price range for a $1.7 billion fully diluted market value.

Prime Medicine Announces Pricing of Upsized Initial Public Offering

Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced the pricing of its upsized initial public offering of 10,294,118 shares of its common stock at a price to the public of $17.00 per share. All of the shares are being offered by Prime Medicine. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Prime Medicine, are expected to be $175.0 million. In addition, the underwriters have a 30-day option to purchase up to 1,544,117 additional shares of common stock at the initial public offering price less underwriting discounts and commissions.

Prime Medicine Launches with $315 Million Financing to Deliver on the Promise of Prime Editing

Prime Medicine™, a company delivering on the promise of Prime Editing to provide lifelong cures to patients, today announced its launch with $315 million in financing. The financing comprised a $115 million Series A; based on the rapid progress of the science and the company, Prime Medicine expanded its syndicate support with a $200M Series B financing approximately nine months after the company began operations. Investors in the Series A included ARCH Venture Partners, F-Prime Capital, GV, and Newpath Partners.
Browse Insights
Updated on: Dec 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.